Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Olema Pharmaceuticals director Sandra Horning received a new stock option grant. The award covers 29,500 shares of common stock at an exercise price of $9.51 per share and expires on June 18, 2036.
The options vest in 12 equal monthly installments starting June 18, 2026, subject to her continuous service. Any remaining unvested portion will fully vest on the date of Olema’s next annual stockholder meeting if it occurs before the monthly schedule is complete.
Olema Pharmaceuticals director Raman Prakash received a stock option grant for 29,500 shares of common stock. The option has an exercise price of $9.51 per share and expires on June 18, 2036. It was awarded as compensation rather than purchased on the open market.
The 29,500 underlying shares vest in 12 equal monthly installments starting on June 18, 2026, as long as Prakash continues in service through each vesting date. Any unvested portion will fully vest on the date of Olema’s next annual stockholder meeting if it is not already fully vested and he remains in service through that date.
Olema Pharmaceuticals director Andrew Rappaport received a new stock option grant as part of his compensation. He was awarded options covering 29,500 shares of Olema common stock at an exercise price of $9.51 per share, held directly. The options expire on June 18, 2036.
The grant vests in 12 equal monthly installments starting June 18, 2026, as long as he continues to serve the company. If the options are not fully vested earlier, they vest in full on the date of Olema’s next annual stockholder meeting, again subject to continued service.
Olema Pharmaceuticals director Graham G. Walmsley received a new stock option grant for 29,500 shares of common stock. The option has an exercise price of $9.51 per share and expires on June 18, 2036. The award vests in 12 equal monthly installments starting June 18, 2026, with any remaining unvested portion vesting in full on the date of Olema’s next annual stockholder meeting, in each case contingent on his continued service. Following this grant, Walmsley holds 29,500 stock options directly.
Olema Pharmaceuticals, Inc. reported the results of its annual stockholder meeting held on June 17, 2026. Stockholders elected four Class III directors—Sean Bohen, Scott Garland, Yi Larson, and Andrew Rappaport—to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also approved, on an advisory basis, the executive compensation program, with about 68 million votes in favor and relatively few votes against or abstaining. In addition, they strongly ratified the Audit Committee’s selection of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026. No other matters were brought to a vote.
Olema Pharmaceuticals has entered a clinical trial collaboration and supply agreement with Bayer to test its investigational KAT6 inhibitor OP-3136 with Bayer’s androgen receptor inhibitor NUBEQA (darolutamide) in metastatic castration-resistant prostate cancer.
The planned Phase 1b/2 study will evaluate safety, tolerability, and preliminary anti-tumor activity of the combination in approximately 36 patients with mCRPC and is expected to start in the second half of 2026. Bayer will supply darolutamide, while Olema will lead the trial.
All clinical data and inventions related to the combination will be jointly owned, and Olema will retain full global commercial and marketing rights to OP-3136. This is the first clinical collaboration for OP-3136 and extends its development beyond breast cancer into prostate cancer.
Olema Pharmaceuticals reported encouraging preliminary Phase 1 data for OP-3136, its oral KAT6 inhibitor, in advanced solid tumors. In 32 heavily pretreated patients across ER+/HER2- breast, metastatic castration-resistant prostate, and metastatic non-small cell lung cancers, doses from 2 mg to 45 mg once daily were evaluated.
OP-3136 was well-tolerated with no dose-limiting toxicities, no grade 4 or 5 treatment-related adverse events, and no discontinuations due to treatment-related events. Among 19 response-evaluable patients, tumor shrinkage occurred in 13, including 3 partial responses, 2 of which were confirmed. Eleven patients remain on treatment, with the longest treatment duration at 62 weeks. OP-3136 showed rapid, sustained reduction of its histone target and predictable, dose-proportional pharmacokinetics, supporting continued monotherapy and combination development.
Olema Pharmaceuticals: Bain Capital Life Sciences Opportunities IV, L.P. filed an amendment to its Schedule 13G/A reporting that, as of March 31, 2026, it beneficially owned 2,960,036 shares and a pre-funded warrant exercisable for 4,513,202 shares, together representing approximately 8.2% of the common stock.
The filing states 7,473,238 shares are held with shared voting and dispositive power and that the pre-funded warrant cannot be exercised to exceed a 9.99% beneficial ownership limitation. Shares outstanding were cited as 87,156,961 as of March 11, 2026.
Janus Henderson Group plc reports beneficial ownership of 7,108,488 shares of Olema Pharmaceuticals, Inc. common stock, representing 8.2% of the class. The filing states the Asset Managers exercise shared voting and shared dispositive power over those shares. The Asset Managers act on behalf of multiple Managed Portfolios and the filing notes that the Asset Managers do not have the right to receive dividends or sale proceeds from certain securities held in those Managed Portfolios and disclaim ownership associated with those rights.
Olema Pharmaceuticals reported a larger quarterly loss as it invests heavily in cancer drug development, but ended the period with substantial cash. For the three months ended March 31, 2026, net loss was $53.1 million compared with $30.4 million a year earlier, driven mainly by higher research and development expenses of $49.2 million and general and administrative expenses of $8.8 million.
Total assets were $530.6 million, including $505.3 million in cash, cash equivalents and marketable securities. Operating cash outflow was $46.0 million, largely offset by $41.9 million of net proceeds from an at-the-market stock program. Management believes existing cash, securities and available debt capacity will fund the current operating plan for at least 12 months. As of May 7, 2026, common shares outstanding were 87.3 million, excluding 13.6 million shares issuable upon exercise of pre-funded warrants.